‌

US Patent 11780844 Compounds and methods for treatment of viral infections

Patent 11780844 was granted and assigned to Gilead Sciences on October, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent attributes

Patent Applicant

Gilead Sciences

Current Assignee

Gilead Sciences

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Dustin S. Siegel

Mark J. Bartlett

Daniel H. Byun

Xianhuang Zeng

Richard L. Mackman

Jennifer L. Cosman Ellis

Rao V. Kalla

Yifan Deng

Date of Patent

October 10, 2023

Patent Application Number

18117858

Date Filed

March 6, 2023

Patent Citations

US Patent 7285658 Nucleotide mimics and their prodrugs

US Patent 7368437 Bicyclic heterocycles, processes for their preparation and their use as herbicides and pharmaceutical agents

US Patent 7390791 Prodrugs of phosphonate nucleotide analogues

US Patent 7429571 Therapeutic furopyrimidines and thienopyrimidines

US Patent 7514410 Hepatitis C therapies

US Patent 7560434 AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases

US Patent 7598230 Nucleotide mimics and their prodrugs

US Patent 7608597 Methods and compositions for treating hepatitis C virus

...

Patent Citations Received

US Patent 12012431 Methods of preparing 1′-cyano nucleosides

0

Patent Primary Examiner

CPC Code

Patent abstract

Compounds and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11780844 Compounds and methods for treatment of viral infections

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.